Documentary record · October 19, 2026 edition
MHRA strengthens antidepressant safety information
SAFETY COMMUNICATION — PHASED IMPLEMENTATION
SOURCE-VERIFIED · HUMAN REVIEW PENDING
Event date
October 15, 2026
Authority
UK MHRA (review initiated by the Commission on Human Medicines)
Lifecycle state
SAFETY COMMUNICATION — PHASED IMPLEMENTATION
Source published
October 15, 2026
Source checked
October 19, 2026
Published on KPSGILL
What changed
- Patient leaflets will add a boxed warning signposting information on suicidal thoughts and behaviours.
- A patient card is expected in or on the pack.
- Leaflets for certain antidepressants will name "Post SSRI Sexual Dysfunction" (PSSD), the risk of sexual symptoms continuing after treatment stops.
- An ancillary safety leaflet for first appointments and existing patients will be available in 2027.
MHRA: "It's imperative that patients do not stop taking these medicines without first speaking to their healthcare professional." It adds that for most people "the benefits outweigh the risks".
Does not establish
a new risk discovered in October, a U.S. FDA labeling change, or advice to stop treatment.
Sources
- MHRA antidepressant safeguards Primary · 2026-10-15 · checked 2026-10-19
Related on this site
Register: the record store · record id mhra-antidepressant-safety-information-2026-10-15 · SOURCE-VERIFIED · HUMAN REVIEW PENDING.